Lakeshore Biopharma Co Ltd (LSB) Gross Profit Margin starting from the fourth quarter 2024 to fourth quarter 2023, Profitability Trends and Ranking, Fundamental Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Gross Margin
• EBITDA Margin
• Operating Margin
• Net Margin
• Pre-Tax Margin
• Effective Tax Rate
• Free Cash Flow Margin
• Cash Flow Margin
Lakeshore Biopharma Co Ltd  (NASDAQ: LSB)


Lakeshore Biopharma Co Ltd's Gross Profit Margin by quarter

Trends, Rankings, Statistics


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

LSB Gross Profit Margin (Mar 31 2024)
Q4 		0
Q3 		0
Q2 		0
Q1 		(Mar 31 2023)
Q4
Y / Y Revenue Change -19.18 %
Seq. Revenue Change -
Revenue In Millions $80.82
Gross Profit Margin 79.48 %
Gross Profit Margin Total Ranking # 704
Gross Profit In Millions $64.23
Y / Y Gross Profit Change -17.32 %
Seq. Gross Profit Change -


Commenting fourth quarter 2024 Gross Profit Margin



Observing fourth quarter 2024 results within Major Pharmaceutical Preparations industry 67 other companies have achieved higher Gross Profit Margin. While Gross Profit Margin overall ranking has deteriorated relative to the three months before, from to 704.
Learn about Gross Margin
LSB's Gross Profit Margin fourth quarter 2024 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 68
Healthcare Sector # 118
Overall # 695

Gross Profit Margin Statistics
High Average Low
79.48 % 78.58 % 77.68 %
(Mar 31 2024)   (Mar 31 2023)


LSB Gross Income Trends • More of LSB's Profitabilty Ratios • LSB Stock Quotes and Charts


Other Gross Profit Margin Profitability Ratios
LSB's Cumulative Gross Profit Margin
Major Pharmaceutical Preparations Industry Gross Profit Margin Trends and Statistics
Healthcare Sector Gross Profit Margin Statistics
Gross Profit Margin Profitability Trends for overall market
LSB's Gross Profit Margin Profitability versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Gross Profit Margin
Lowest Ranking Gross Profit Margin
Gross Profit Margin Profit Margin for LSB's Competitors
Gross Profit Margin Profit Margin for Lakeshore Biopharma Co Ltd's Suppliers
Gross Profit Margin Profit Margin for LSB's Customers

You may also want to know
LSB's Annual Growth Rates LSB's Profitability Ratios LSB's Asset Turnover Ratio LSB's Dividend Growth
LSB's Roe LSB's Valuation Ratios LSB's Financial Strength Ratios LSB's Gross Profit Growth
LSB's Roa LSB's Inventory Turnover Ratio LSB's Growth Rates LSB's Dividend Comparisons


Companies with similar Gross Profit Margin in the quarter ending Mar 31 2024, within Major Pharmaceutical Preparations Industry Gross Profit MarginMar 31 2024 MRQ Gross ProfitMar 31 2024 MRQ Revenue
Bridgebio Pharma Inc   99.72 %$ 210.522  Millions$ 211.120  Millions
Corcept Therapeutics Inc  98.27 %$ 144.273  Millions$ 146.808  Millions
Ptc Therapeutics inc   98.24 %$ 206.418  Millions$ 210.118  Millions
Uniqure N v   98.23 %$ 8.335  Millions$ 8.485  Millions
Ionis Pharmaceuticals Inc   98.20 %$ 117.346  Millions$ 119.497  Millions
Therapeuticsmd Inc   97.86 %$ 0.229  Millions$ 0.234  Millions
Lexicon Pharmaceuticals Inc   97.26 %$ 1.099  Millions$ 1.130  Millions
Pyxis Oncology Inc   97.06 %$ 15.671  Millions$ 16.146  Millions
Macrogenics Inc   97.03 %$ 8.834  Millions$ 9.104  Millions
Blueprint Medicines Corporation  96.68 %$ 92.925  Millions$ 96.116  Millions
Gyre Therapeutics Inc   96.40 %$ 26.193  Millions$ 27.172  Millions
Travere Therapeutics Inc   96.36 %$ 39.870  Millions$ 41.374  Millions
Avadel Pharmaceuticals Plc  96.25 %$ 25.656  Millions$ 26.656  Millions
Adc Therapeutics Sa  95.86 %$ 17.305  Millions$ 18.053  Millions
Apellis Pharmaceuticals Inc   95.42 %$ 164.425  Millions$ 172.325  Millions
Deciphera Pharmaceuticals Inc   95.36 %$ 42.911  Millions$ 44.999  Millions
Zevra Therapeutics Inc   94.89 %$ 3.250  Millions$ 3.425  Millions
Urogen Pharma Ltd   94.46 %$ 17.053  Millions$ 18.053  Millions
Karyopharm Therapeutics Inc   94.23 %$ 31.215  Millions$ 33.126  Millions
Arcutis Biotherapeutics Inc   93.43 %$ 46.313  Millions$ 49.569  Millions
Amylyx Pharmaceuticals Inc   93.29 %$ 82.698  Millions$ 88.643  Millions
Rigel Pharmaceuticals Inc  93.14 %$ 27.509  Millions$ 29.534  Millions
Vanda Pharmaceuticals Inc   92.75 %$ 44.022  Millions$ 47.462  Millions
Regeneron Pharmaceuticals Inc   92.36 %$ 2,904.600  Millions$ 3,145.000  Millions
Agios Pharmaceuticals Inc   92.34 %$ 7.562  Millions$ 8.189  Millions
Silo Pharma Inc  91.90 %$ 0.017  Millions$ 0.018  Millions
Optinose Inc   91.73 %$ 13.649  Millions$ 14.880  Millions
Axsome Therapeutics Inc   91.60 %$ 68.702  Millions$ 74.999  Millions
Tg Therapeutics Inc   91.43 %$ 58.033  Millions$ 63.474  Millions
Ocular Therapeutix Inc   91.02 %$ 13.448  Millions$ 14.774  Millions




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.